CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Pharmaceutical Technology
Original article

GSK bolsters oncology pipeline with $750m Chimagen TCE deal  

Positive
AI Analysis

Summary

GSK acquired Chimagen's TCE platform for $750 million to bolster its oncology pipeline, with plans to advance the therapy into Phase 1 clinical trials for multiple myeloma in 2027.

Clinical Trial Data

Phase

Phase 1

Importance:7/10
Sentiment:
0.60
M&ATCEoncologymultiple myelomaPhase 1
Related Companies

Read the original article

Published by Pharmaceutical Technology on September 15, 2026 10:47 AM

Read Original